Managed access programmes (MAPs) are often unfamiliar territory for clinical teams, as their purpose and regulatory environment are very different from randomised controlled trials. ICON's Veronica Gutierrez Martinez considers how Sponsors need to plan carefully before undertaking a MAP so that they have the resources, processes, and tools in place to support the inevitable demand.

Read article